PEGPH20 With Nab-paclitaxel/Gemcitabine in Pancreatic Cancer

August 14, 2015
Andrew Hendifar, MD, MPH

Andrew Hendifar, MD, MPH, assistant professor of medicine, Cedars Sinai Medical Center and the David Geffen School of Medicine, discusses PEGPH20 with nab-paclitaxel/gemcitabine in pancreatic cancer.

Today, pancreatic cancer is treated with multagent chemotherapy, but unfortunately, the results are not very good, with a five-year survival rate of 7%, said Hendifar. PEGH20, a PEGylated form of rHuPH20, is an enzyme inhibitor of polyuronides, and Hendifar and his team hypothesized that using PEGH20, in addition to chemotherapy, would help to deliver the chemotherapy to the tumor.

Andrew Hendifar, MD, MPH, assistant professor of medicine, Cedars Sinai Medical Center and the David Geffen School of Medicine, discusses PEGPH20 with nab-paclitaxel/gemcitabine in pancreatic cancer.